Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Randomization between:
* Experimental group: transcutaneous auricular vagus nerve stimulation (taVNS)
* Control group: placebo using the same device that does not deliver electrical stimulation
Patient candidate for first line chemotherapy treatment (alone, neoadjuvant or adjuvant)
Patient affiliated to an appropriate social security system
Patient who has signed informed consent obtained before any trial related activities
You may not be if
Patient with an active implantable medical device or any other implanted electronic or electrical device (pacemaker, defibrillator, etc.)
Dermatological problems in the area where stimulation electrodes are applied
Recent history (\<2 years) of epileptic seizures
Proven severe cardiovascular disease (such as known FEV \<40%, severe valvulpathy…) or HRV analysis not possible (such as uncontrolled atrial fibrillation)
Serious ear pathology
Documented vegetative neuropathy
Unusual morphology of the left ear which does not allow the use of the device
Patient with a cochlear implant near to the stimulation site
Impaired cognitive abilities
Concurrent other malignancy (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)
Pregnant or breastfeeding woman
Simultaneous participation in another clinical study that may compromise the conduct of this study.
Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Patient deprived of liberty or placed under the authority of a tutor
